medications-money-cure-tablets

Amarin gains positive opinion from Spanish Drug Pricing Committee for national reimbursement of Vazkepa in Spain

July 26, 2023
Sales and Marketing Amarin, Cardiology, Spanish Drug Pricing Committee, Vazkepa, cardiovascular

Amarin has announced that the Spanish Drug Pricing Committee has recommended the national reimbursement of Vazkepa (icosapent ethyl) in Spain …

Pharma pill manufacturing

Biovian announces investment in manufacturing facility in Finland

July 26, 2023
Manufacturing and Production Biovian, Pharmacy, facility, manufacturing

Biopharmaceutical based contract development and manufacturing organisation (CDMO) Biovian OY has announced an investment of over €50m to expand its …

pills-384846_960_720

AbbVie announces first patient dosed in phase 3 trial of upadacitinib in hidradenitis suppurativa

July 25, 2023
Research and Development AbbVie, Dermatology, HS, Rinvoq, clinical trial, upadacitinib

AbbVie has announced that the first patient has been dosed in its phase 3 Step-Up trial assessing Rinvoq (upadacitinib) for …

vaccinessssssssssssssssssss_1

Bavarian Nordic announces RSV vaccine did not meet all primary endpoints in phase 3 trial

July 25, 2023
Medical Communications Bavarian Nordic, Infections and infestations, RSV, Vaccine, clinical trial

Bavarian Nordic has announced that its phase 3 clinical trial of MVA-BN, its respiratory syncytial virus (RSV) vaccine candidate for …

Vaccine image

ViiV Healthcare gains positive CHMP opinion for cabotegravir for HIV prevention

July 24, 2023
Medical Communications CHMP, EMA, HIV, HIV/AIDS, ViiV Healthcare, cabotegravir

GSK has announced that ViiV Healthcare has received a positive opinion from the European Medicines Agency’s (EMA) Committee for Medicinal …

Alnylam and Roche partner for RNAi therapeutic for treatment of hypertension

July 24, 2023
Research and Development Alnylam, Cardiology, Roche, hypertension, rnai, zilebesiran

Alnylam Pharmaceuticals has announced that it has entered a strategic agreement with Roche for the development and commercialisation of zilebesiran, …

stethoscope_and_background_doctor

Aevice Health gains FDA clearance for respiratory monitoring platform

July 21, 2023
Research and Development Aevice Health, Devices, FDA, respiratory monitoring

Remote respiratory monitoring solutions company Aevice Health has announced that it has received clearance from the US Food and Drug …

BioIVT acquires PrecisionMed for neurology and oncology research

July 21, 2023
Sales and Marketing Neurology, Oncology, neurology, oncology

BioIVT has announced that it has acquired PrecisionMed, a leading supplier of high-quality human biological material for genetics, drug discovery …

WHO releases Medical Product Alert for contaminated cough syrup

July 20, 2023
Medical Communications Pharmacy, WHO, cough syrups, medical product alert, world health organization

The World Health Organization (WHO) has shared a Medical Product Alert for an additional contaminated cough syrup medicine identified in …

Vaccine image

Pfizer shares new data from phase 2 trial for GBS maternal vaccine candidate

July 20, 2023
Research and Development Immunology, Pfizer, Vaccine, clinical trial

Pfizer has announced new data from its phase 2 study which assessed its hexavalent capsular polysaccharide (CPS) conjugate Group B …

Santhera closes exclusive license agreement with Catalyst Pharmaceuticals for Vamorolone

July 19, 2023
Medical Communications License Agreement, Musculo-skeletal disorder, Vamorolone, catalyst, santhera

Santhera Pharmaceuticals has announced the closing of its exclusive North American license agreement for vamorolone with Catalyst Pharmaceuticals. The agreement …

Renibus Therapeutics announces $47m financing for phase 3 trial

July 19, 2023
Business Services Cardiology, Financing, Renibus Therapeutics, clinical trial

Clinical stage biopharmaceutical company Renibus Therapeutics has announced that it has raised $47m from the initial closing of its Series …

alzheimers_brain

Eli Lilly shares results from phase 3 trial of donanemab for Alzheimer’s treatment

July 18, 2023
Research and Development Alzheimer's, Eli Lilly, Neurology, clinical trial, donanemab

Eli Lilly has presented full results from the phase 3 TRAILBLAZER-ALZ 2 study which assessed donanemab for the treatment of …

1200px-vaccine_image_1_1

FDA approves AstraZeneca’s drug to prevent RSV in babies and young children

July 18, 2023
Research and Development AstraZeneca, FDA, Immunology, RSV, Vaccine, paediatrics

The US Food and Drug Administration (FDA) has announced that it has approved Beyfortus (nirsevimab-alip) for the prevention of respiratory …

Inizio Engage launches Patient Access Services – an integrated suite of patient support services to enhance access and adherence for specialty therapies

July 18, 2023
Business Services Inizio Engage, Patient Access Services, Pharmacy, patient support

Fort Washington, US — Inizio Engage is pleased to announce the launch of Patient Access Services. This custom-built, integrated suite of patient support services …

Alnylam shares positive results from phase 1 trial

July 17, 2023
Research and Development ALN-APP, Alnylam, Alzheimer's disease, Cerebral Amyloid Angiopathy, Neurology, clinical trial

Alnylam Pharmaceuticals has announced positive interim results for the ongoing single ascending dose section of its phase 1 study of …

Eli Lilly to acquire Versanis Bio for $1.9bn

July 17, 2023
Sales and Marketing Cardiology, Eli Lilly, Versanis Bio, acquisition, cardiometabolic diseases

Eli Lilly and Versanis Bio have announced a definitive agreement for Lilly to acquire Versanis, a private clinical-stage biopharmaceutical company …

FDA approves first OTC daily oral contraceptive pill

July 14, 2023
Medical Communications Contraception, FDA, OTC, Opill, contraceptive pill

The US Food and Drug Administration (FDA) has announced that it has approved the Opill (norgestrel) tablet for nonprescription use …

Chemotherapy

EMA accepts Astellas’ MAA for Zolbetuximab

July 14, 2023
Medical Communications Astellas, Cancer, EMA, Oncology, zolbetuximab

Astellas Pharma has announced that the European Medicines Agency (EMA) has accepted the company’s marketing authorisation application (MAA) for regulatory …

Recursion and NVIDIA partner for AI-enabled drug discovery developments

July 13, 2023
Research and Development AI, Pharmacy, Recursion, drug discovery

Clinical stage biotech company Recursion has announced a $50m investment by NVIDIA, intended to accelerate the development of its AI …

The Gateway to Local Adoption Series

Latest content